• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性活动性肝炎和酒精性肝硬化患者的肝血流量、安替比林清除率及安替比林代谢产物形成清除率

Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.

作者信息

Bauer L A, O'Sullivan T, Reiss W G, Horn J R, Opheim K, Strandness D E, Carithers R L

机构信息

Department of Pharmacy, University of Washington, Seattle 98195.

出版信息

Br J Clin Pharmacol. 1994 Apr;37(4):375-81. doi: 10.1111/j.1365-2125.1994.tb04292.x.

DOI:10.1111/j.1365-2125.1994.tb04292.x
PMID:8018459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1364739/
Abstract

Duplex scanning was used to measure liver blood flow (hepatic artery and main branches of the portal and hepatic veins) in six healthy subjects, five cirrhotic patients, and six hepatitis patients. Antipyrine clearance and formation clearances to its metabolites were also measured. Compared with healthy control subjects, cirrhotic patients had a lower hepatic vein blood flow (-76%, P < 0.05). This was due primarily to a lower portal vein blood flow (-36%, NS). A statistically significant difference in liver blood flow between patients with hepatitis and normal subjects was not detected. Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008). Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were not significantly different in hepatitis patients compared with the healthy subjects (hepatitis patients: t1/2 = 14.3 +/- 3.7 h, CL = 29.3 +/- 8.5 ml h-1 kg-1, AUC = 498 +/- 142 mg l-1 h). The volume of distribution of antipyrine was similar in all three groups of subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

采用双功扫描测量了6名健康受试者、5名肝硬化患者和6名肝炎患者的肝脏血流(肝动脉以及门静脉和肝静脉的主要分支)。还测量了安替比林清除率及其代谢产物的生成清除率。与健康对照受试者相比,肝硬化患者的肝静脉血流较低(-76%,P<0.05)。这主要是由于门静脉血流较低(-36%,无统计学意义)。未检测到肝炎患者与正常受试者之间肝脏血流的统计学显著差异。与健康受试者相比,肝硬化患者的安替比林半衰期、清除率以及血清药物浓度-时间曲线下面积有显著差异(平均值±标准差-健康对照组:t1/2 = 13.7±3.0小时,CL = 30.0±8.6毫升·小时-1·千克-1,AUC = 549±139毫克·升-1·小时;肝硬化患者:t1/2 = 32.4±1.7小时,CL = 12.3±2.1毫升·小时-1·千克-1,AUC = 1061±218毫克·升-1·小时;P<0.008)。与健康受试者相比,肝炎患者的安替比林半衰期、清除率以及血清药物浓度-时间曲线下面积无显著差异(肝炎患者:t1/2 = 14.3±3.7小时,CL = 29.3±8.5毫升·小时-1·千克-1,AUC = 498±142毫克·升-1·小时)。安替比林的分布容积在所有三组受试者中相似。(摘要截短至250字)

相似文献

1
Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.慢性活动性肝炎和酒精性肝硬化患者的肝血流量、安替比林清除率及安替比林代谢产物形成清除率
Br J Clin Pharmacol. 1994 Apr;37(4):375-81. doi: 10.1111/j.1365-2125.1994.tb04292.x.
2
Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis.天然人干扰素亚慢性治疗对慢性肝炎患者安替比林清除率及肝功能的影响
J Clin Pharmacol. 1990 Jun;30(6):562-7. doi: 10.1002/j.1552-4604.1990.tb03621.x.
3
Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.酒精性肝硬化患者的安替比林清除率及代谢产物形成情况
Br J Clin Pharmacol. 1984 Nov;18(5):707-15. doi: 10.1111/j.1365-2125.1984.tb02533.x.
4
Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C.慢性丙型肝炎患者的安替比林清除率及代谢物排泄情况
J Hepatol. 1995 Jan;22(1):17-21. doi: 10.1016/0168-8278(95)80254-1.
5
Alterations in the disposition of differently cleared drugs in patients with cirrhosis.肝硬化患者中不同清除方式药物处置的改变。
Clin Pharmacol Ther. 1979 Aug;26(2):221-7. doi: 10.1002/cpt1979262221.
6
Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.在轻度和中度肝硬化患者中,阿芬太尼诱导的瞳孔缩小作为阿芬太尼药代动力学的替代指标。
Clin Pharmacokinet. 2007;46(3):261-70. doi: 10.2165/00003088-200746030-00006.
7
Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients.慢性和肿瘤性肝病中安替比林清除率:518例患者的研究
J Gastroenterol Hepatol. 1998 May;13(5):460-6. doi: 10.1111/j.1440-1746.1998.tb00668.x.
8
Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.有或无肝硬化的酒精性患者中奎尼丁处置与安替比林消除及异喹胍代谢型的关系
Int J Clin Pharmacol Res. 1989;9(5):319-25.
9
Prediction of response to interferon in patients with chronic active hepatitis C, and evidence that this improves hepatic metabolic function.慢性丙型活动性肝炎患者对干扰素反应的预测,以及干扰素可改善肝脏代谢功能的证据。
Gastroenterol Jpn. 1991 Jul;26 Suppl 3:243-6. doi: 10.1007/BF02779310.
10
Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.酒精性和非酒精性肝硬化患者的安替比林消除情况。
Z Gastroenterol. 1993 Jan;31(1):15-9.

引用本文的文献

1
Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature.炎症对成人细胞色素P450活性的影响:文献系统综述
Front Pharmacol. 2021 Nov 16;12:733935. doi: 10.3389/fphar.2021.733935. eCollection 2021.
2
Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.肝病患者的临床药代动力学和药效学考量。最新进展。
Clin Pharmacokinet. 1995 Nov;29(5):370-91. doi: 10.2165/00003088-199529050-00005.

本文引用的文献

1
Hepatic circulation in cirrhosis of the liver.肝硬化时的肝循环。
Circulation. 1952 Mar;5(3):419-29. doi: 10.1161/01.cir.5.3.419.
2
Estimation of hepatic blood flow with indocyanine green.用吲哚菁绿评估肝血流量。
J Clin Invest. 1962 May;41(5):1169-79. doi: 10.1172/JCI104570.
3
The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.吲哚菁绿在肝血流测量及肝功能检测中的应用。
Clin Sci. 1961 Aug;21:43-57.
4
Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.性别及口服避孕药类固醇对抗菌素代谢物形成的影响。
Clin Pharmacol Ther. 1982 Aug;32(2):240-6. doi: 10.1038/clpt.1982.154.
5
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.人体中安替比林不同代谢途径的研究。口服与静脉注射给药以及尿液收集时间的影响。
Eur J Clin Pharmacol. 1982;21(5):433-41. doi: 10.1007/BF00542332.
6
Simplified high performance liquid chromatographic quantitation of antipyrine.安替比林的简化高效液相色谱定量法
J Chromatogr Sci. 1984 Jun;22(6):239-40. doi: 10.1093/chromsci/22.6.239.
7
Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine.血浆、唾液和尿液中安替比林及其主要代谢物(包括4,4'-二羟基安替比林)的高效液相色谱自动测定法
J Chromatogr. 1983 Dec 9;278(2):367-78.
8
Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.酒精性肝硬化患者的安替比林清除率及代谢产物形成情况
Br J Clin Pharmacol. 1984 Nov;18(5):707-15. doi: 10.1111/j.1365-2125.1984.tb02533.x.
9
Clearance of antipyrine-dependence of quantitative liver function.安替比林清除率与定量肝功能的相关性
Eur J Clin Invest. 1974 Apr;4(2):129-34. doi: 10.1111/j.1365-2362.1974.tb00383.x.
10
Clearance concepts in pharmacokinetics.药代动力学中的清除概念。
J Pharmacokinet Biopharm. 1973 Apr;1(2):123-36. doi: 10.1007/BF01059626.